Urszula Wojciechowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Urszula Wojciechowska has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Joanna Didkowska
Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
8 shared publications - Florentino Luciano Caetano dos Santos
Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
5 shared publications - Irmina Maria Michalek
Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
5 shared publications - Iwona Wnętrzak
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland
2 shared publications - Jakub Dobruch
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Professor W. Orlowski, 00-416 Warsaw, Poland
2 shared publications - Mateusz Czajkowski
Department of Urology, Medical University of Gdańsk, Mariana Smoluchowskiego 17 Street, 80-214 Gdańsk, Poland
2 shared publications
Latest Publications
- Open Access
Changing Burden of Haematolymphoid Tumours in AYA in Poland: Organizational Challenges for the Healthcare System (Current Status and Future Perspectives)
Background/Objectives: Hematological malignancies (HMs) are an important component of the cancer burden in adolescents and young adults (AYA, 15–39 years), requiring long-term specialized care. In Poland, recent healthcare reforms under the National Oncology Network (KSO) have not formally included haemato-oncology or AYA-specific needs. Methods: A population-based study was conducted using data from the Polish National Cancer Registry. AYAs diagnosed with HM between 2000 and 2022 were included. Descriptive analyses and projections were based on cases diagnosed between 2000 and 2022, whereas age-specific incidence trend analyses were restricted to the 2015–2022 period. Tumours were classified according to the HAEMCARE framework. Age-standardized incidence rates (ASIRs), annual percentage changes (APCs), and short-term projections through 2028 were estimated using generalized linear models. Additionally, data from the National Health Fund (NFZ) were analyzed to assess the geographical distribution of reimbursed drug programmes dedicated to selected HMs. Results: A total of approximately 23,000 AYA patients diagnosed with HMs were identified. Hodgkin lymphomas (HL) were the predominant tumour type across all age groups, while lymphoblastic leukemia/lymphoma was most common among younger AYAs and diffuse large B-cell lymphoma (DLBCL) increased in relative importance with age. Between 2015 and 2022, ASIRs remained stable only in two age groups (20–24 and 25–29), whereas statistically significant increases were observed among individuals aged 15–19, 30–34 and 35–39 years. Despite largely stable incidence patterns, projections indicated a growing absolute number of cases for DLBCL and follicular lymphomas. Analysis of NFZ data revealed substantial regional variation in the availability of reimbursed drug programmes, with up to six-fold differences in facility density between voivodships. Conclusions: HM epidemiology among AYAs in Poland is characterized by increasing incidence in selected lymphoma subtypes alongside declining mortality. Incorporating haemato-oncology and AYA-specific needs into national cancer planning frameworks should therefore be considered essential for future healthcare system preparedness.
Open AccessChanging Burden of Haematolymphoid Tumours in AYA in Poland: Organizational Challenges for the Healthcare System (Current Status and Future Perspectives)
Background/Objectives: Hematological malignancies (HMs) are an important component of the cancer burden in adolescents and young adults (AYA, 15–39 years), requiring long-term specialized care. In Poland, recent healthcare reforms under the National Oncology Network (KSO) have not formally included haemato-oncology or AYA-specific needs. Methods: A population-based study was conducted using data from the Polish National Cancer Registry. AYAs diagnosed with HM between 2000 and 2022 were included. Descriptive analyses and projections were based on cases diagnosed between 2000 and 2022, whereas age-specific incidence trend analyses were restricted to the 2015–2022 period. Tumours were classified according to the HAEMCARE framework. Age-standardized incidence rates (ASIRs), annual percentage changes (APCs), and short-term projections through 2028 were estimated using generalized linear models. Additionally, data from the National Health Fund (NFZ) were analyzed to assess the geographical distribution of reimbursed drug programmes dedicated to selected HMs. Results: A total of approximately 23,000 AYA patients diagnosed with HMs were identified. Hodgkin lymphomas (HL) were the predominant tumour type across all age groups, while lymphoblastic leukemia/lymphoma was most common among younger AYAs and diffuse large B-cell lymphoma (DLBCL) increased in relative importance with age. Between 2015 and 2022, ASIRs remained stable only in two age groups (20–24 and 25–29), whereas statistically significant increases were observed among individuals aged 15–19, 30–34 and 35–39 years. Despite largely stable incidence patterns, projections indicated a growing absolute number of cases for DLBCL and follicular lymphomas. Analysis of NFZ data revealed substantial regional variation in the availability of reimbursed drug programmes, with up to six-fold differences in facility density between voivodships. Conclusions: HM epidemiology among AYAs in Poland is characterized by increasing incidence in selected lymphoma subtypes alongside declining mortality. Incorporating haemato-oncology and AYA-specific needs into national cancer planning frameworks should therefore be considered essential for future healthcare system preparedness.
- Open Access
Epidemiology of Primary Urethral Cancer: Insights from Four European Countries with a Focus on Poland
Background/Purpose: Primary urethral cancer is a rare malignancy, accounting for less than 1% of all urogenital cancers. Current epidemiological data from Europe are scarce and outdated. Therefore, the analyzes and comparison of the incidence and mortality of PUC in selected European countries, with particular focus on Poland, based on the most recent available registry data, were performed. Methods: Our study is based on country-level data and is descriptive in nature. Incidence data for PUC were obtained from the national cancer registries of Poland, Latvia, Slovenia, and Hungary. Mortality data were sourced from the WHO Mortality Database. Age-standardized incidence rates were calculated for two time intervals (2000–2009 and 2010–2019). Age-standardized mortality rates for individuals aged ≥45 years were calculated using the European Standard Population (ESP2013). Trends in incidence and mortality in Poland were analyzed using a five-year moving average. Results: The highest incidence of PUC was observed in Hungary, while Poland showed the lowest incidence. Latvia had the highest ASMRs for both sexes, whereas Poland and Greece reported the lowest mortality rates. Despite slight annual fluctuations, the overall PUC mortality rate in Poland has remained stable. Our study is limited by the relatively short analyzed period (2000–2021), restricted availability of C68.0 incidence data from national cancer registries, and incomplete mortality data in the WHO mortality database. Conclusions: This first contemporary comparative analysis of PUC epidemiology in Europe highlights the rarity of this malignancy and the limited data availability. Based on the knowledge drawn from the literature presented in the article on the impact of centralization on the increase in overall survival and the decrease in mortality in rare cancers, the authors believe that centralization of care can improve PUC patient outcomes.
Open AccessEpidemiology of Primary Urethral Cancer: Insights from Four European Countries with a Focus on Poland
Background/Purpose: Primary urethral cancer is a rare malignancy, accounting for less than 1% of all urogenital cancers. Current epidemiological data from Europe are scarce and outdated. Therefore, the analyzes and comparison of the incidence and mortality of PUC in selected European countries, with particular focus on Poland, based on the most recent available registry data, were performed. Methods: Our study is based on country-level data and is descriptive in nature. Incidence data for PUC were obtained from the national cancer registries of Poland, Latvia, Slovenia, and Hungary. Mortality data were sourced from the WHO Mortality Database. Age-standardized incidence rates were calculated for two time intervals (2000–2009 and 2010–2019). Age-standardized mortality rates for individuals aged ≥45 years were calculated using the European Standard Population (ESP2013). Trends in incidence and mortality in Poland were analyzed using a five-year moving average. Results: The highest incidence of PUC was observed in Hungary, while Poland showed the lowest incidence. Latvia had the highest ASMRs for both sexes, whereas Poland and Greece reported the lowest mortality rates. Despite slight annual fluctuations, the overall PUC mortality rate in Poland has remained stable. Our study is limited by the relatively short analyzed period (2000–2021), restricted availability of C68.0 incidence data from national cancer registries, and incomplete mortality data in the WHO mortality database. Conclusions: This first contemporary comparative analysis of PUC epidemiology in Europe highlights the rarity of this malignancy and the limited data availability. Based on the knowledge drawn from the literature presented in the article on the impact of centralization on the increase in overall survival and the decrease in mortality in rare cancers, the authors believe that centralization of care can improve PUC patient outcomes.
- Open Access
Current Knowledge on UTUC Epidemiology in Poland Compared to Europe
Background: Upper tract urothelial carcinoma (UTUC) is a rare malignancy with limited epidemiological data from Central and Eastern Europe. This study aimed to evaluate long-term trends in UTUC incidence, mortality, and survival in Poland and to compare them with other European countries. Methods: Incidence and mortality data were acquired from Polish National Cancer Registry, Statistics Poland and European Cancer Information System. Age-standardized incidence and mortality rates were calculated using the European Standard Population (ESP 2013). Temporal trends were assessed using Joinpoint regression, and five-year relative survival was estimated with the Pohar–Perme method. Results: Our study demonstrated significantly higher incidence and mortality rates of UTUC across Europe compared to the initial observation period, consistent with the data from Poland. UTUC incidence increased in Poland between 2000 and 2017 (average annual percent change [AAPC] 5.6% in women and 9.9% in men), followed by a decline among women after 2017 (AAPC −1.3%). Mortality initially rose in both sexes but decreased in recent years, particularly in men (AAPC −5.47%). Renal pelvis cancer showed higher incidence and mortality than ureteral cancer. Compared with other European countries, Poland exhibited a smaller gap between incidence and mortality. Five-year relative survival improved over time, reaching 55–56% for renal pelvis cancer and up to 62% for ureteral cancer. Conclusions: UTUC incidence and mortality are rising in Europe, but Poland displays a distinctive epidemiological pattern. Strengthening national cancer registries and implementing centralized care protocols may improve disease management and reduce mortality.
Open AccessCurrent Knowledge on UTUC Epidemiology in Poland Compared to Europe
Background: Upper tract urothelial carcinoma (UTUC) is a rare malignancy with limited epidemiological data from Central and Eastern Europe. This study aimed to evaluate long-term trends in UTUC incidence, mortality, and survival in Poland and to compare them with other European countries. Methods: Incidence and mortality data were acquired from Polish National Cancer Registry, Statistics Poland and European Cancer Information System. Age-standardized incidence and mortality rates were calculated using the European Standard Population (ESP 2013). Temporal trends were assessed using Joinpoint regression, and five-year relative survival was estimated with the Pohar–Perme method. Results: Our study demonstrated significantly higher incidence and mortality rates of UTUC across Europe compared to the initial observation period, consistent with the data from Poland. UTUC incidence increased in Poland between 2000 and 2017 (average annual percent change [AAPC] 5.6% in women and 9.9% in men), followed by a decline among women after 2017 (AAPC −1.3%). Mortality initially rose in both sexes but decreased in recent years, particularly in men (AAPC −5.47%). Renal pelvis cancer showed higher incidence and mortality than ureteral cancer. Compared with other European countries, Poland exhibited a smaller gap between incidence and mortality. Five-year relative survival improved over time, reaching 55–56% for renal pelvis cancer and up to 62% for ureteral cancer. Conclusions: UTUC incidence and mortality are rising in Europe, but Poland displays a distinctive epidemiological pattern. Strengthening national cancer registries and implementing centralized care protocols may improve disease management and reduce mortality.
- Open Access
Risk of suicide in patients with cancer aged 75 years or more – Follow-up of over 400,000 individuals
- Open Access
- 25 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Survival of patients with cancers of the female genital organs in Poland, 2000–2019
The purpose of this study was to estimate cancer survival in Poland between 2000 and 2019 for malignant neoplasms of female genital organs (FGO). We calculated survival in cancer of vulva, vagina, cervix uteri, corpus uteri, ovary, and other unspecified female genital organs. Data were obtained from the Polish National Cancer Registry. We estimated age-standardized 5- and 10-year net survival (NS) with the life table method and the Pohar-Perme estimator using the International Cancer Survival Standard weights. Overall, 231,925 FGO cancer cases were included in the study. The overall FGO age-standardized 5-year NS was 58.2% (95% confidence interval (CI) 57.9–58.5%) and the 10-year NS 51.5% (51.5–52.3%). Between 2000 and 2004 and 2015–2018, the highest statistically significant increase in age-standardized 5-year survival was noted for ovarian cancer at + 5.6% (P < 0.001). The FGO cancer median survival time was 8.8 years (8.6–8.9 years), with a standardized mortality rate of 6.1 (6.0–6.1), and with cause-specific years of life lost at 7.8 years (7.7–7.8 years). Hazard ratios (HR) increased with age at diagnosis (HR = 1.02, 95% CI 1.01–1.03, P = 0.001). Although FGO cancer survivorship has been consistently improving during the last twenty years, additional efforts need to be undertaken to improve survivorship in several FGO cancers.
- 25 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessSurvival of patients with cancers of the female genital organs in Poland, 2000–2019
The purpose of this study was to estimate cancer survival in Poland between 2000 and 2019 for malignant neoplasms of female genital organs (FGO). We calculated survival in cancer of vulva, vagina, cervix uteri, corpus uteri, ovary, and other unspecified female genital organs. Data were obtained from the Polish National Cancer Registry. We estimated age-standardized 5- and 10-year net survival (NS) with the life table method and the Pohar-Perme estimator using the International Cancer Survival Standard weights. Overall, 231,925 FGO cancer cases were included in the study. The overall FGO age-standardized 5-year NS was 58.2% (95% confidence interval (CI) 57.9–58.5%) and the 10-year NS 51.5% (51.5–52.3%). Between 2000 and 2004 and 2015–2018, the highest statistically significant increase in age-standardized 5-year survival was noted for ovarian cancer at + 5.6% (P < 0.001). The FGO cancer median survival time was 8.8 years (8.6–8.9 years), with a standardized mortality rate of 6.1 (6.0–6.1), and with cause-specific years of life lost at 7.8 years (7.7–7.8 years). Hazard ratios (HR) increased with age at diagnosis (HR = 1.02, 95% CI 1.01–1.03, P = 0.001). Although FGO cancer survivorship has been consistently improving during the last twenty years, additional efforts need to be undertaken to improve survivorship in several FGO cancers.
- Open Access
- 17 March 2023
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 17 (3) , 657-662
Suicide risk among adolescents and young adults after cancer diagnosis: analysis of 34 cancer groups from 2009 to 2019
Purpose: We aimed to identify granular groups with an increased risk of suicide among adolescents and young adult (AYA) patients with a previous malignant neoplasm diagnosis. Methods: We deployed a cohort of all cases of primary malignant neoplasms diagnosed between the 1st of January 2009 and the 31st of December 2019 among individuals aged 15–39 years registered in the Polish National Cancer Registry. To assess the risk of suicide in comparison with the general AYA population, we calculated sex–age–year standardized mortality ratios (SMR) with 95% confidence intervals (CI). Results: A total of 50,298 cancer patients (22,111 men and 28,187 women) were included in this study. The risk of suicide for AYA after cancer diagnosis was 2.39-fold higher than that for AYA in the general population (SMR 2.39, 95% CI 1.69 to 3.28). The risk in women (SMR 4.18, 95% CI 1.68 to 8.62) was higher than that in men (SMR 2.18, 95% CI 1.48 to 3.09). A significantly higher risk of suicide was observed in men with testicular cancer (SMR 2.46, 95% CI 1.37 to 4.05). Conclusions: Polish AYA diagnosed with cancer had an almost 2.5-fold higher risk of suicide than the general AYA population. The particular risk group was men with testicular cancer within 2–3 and 5–10 years after cancer diagnosis. Implications for Cancer Survivors: To better identify patients at risk of suicide, there is a need to create or adapt screening tools, educate cancer care providers and family physicians, and integrate psychological services into select cancer care specialties.
- 17 March 2023
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 17 (3) , 657-662
Open AccessSuicide risk among adolescents and young adults after cancer diagnosis: analysis of 34 cancer groups from 2009 to 2019
Purpose: We aimed to identify granular groups with an increased risk of suicide among adolescents and young adult (AYA) patients with a previous malignant neoplasm diagnosis. Methods: We deployed a cohort of all cases of primary malignant neoplasms diagnosed between the 1st of January 2009 and the 31st of December 2019 among individuals aged 15–39 years registered in the Polish National Cancer Registry. To assess the risk of suicide in comparison with the general AYA population, we calculated sex–age–year standardized mortality ratios (SMR) with 95% confidence intervals (CI). Results: A total of 50,298 cancer patients (22,111 men and 28,187 women) were included in this study. The risk of suicide for AYA after cancer diagnosis was 2.39-fold higher than that for AYA in the general population (SMR 2.39, 95% CI 1.69 to 3.28). The risk in women (SMR 4.18, 95% CI 1.68 to 8.62) was higher than that in men (SMR 2.18, 95% CI 1.48 to 3.09). A significantly higher risk of suicide was observed in men with testicular cancer (SMR 2.46, 95% CI 1.37 to 4.05). Conclusions: Polish AYA diagnosed with cancer had an almost 2.5-fold higher risk of suicide than the general AYA population. The particular risk group was men with testicular cancer within 2–3 and 5–10 years after cancer diagnosis. Implications for Cancer Survivors: To better identify patients at risk of suicide, there is a need to create or adapt screening tools, educate cancer care providers and family physicians, and integrate psychological services into select cancer care specialties.
- Open Access
- 12 December 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (3) , 623-631
Changes in the survival of patients with breast cancer: Poland, 2000–2019
Purpose: The main aim of this study was to estimate breast cancer survival in Poland over the period from 2000 to 2019 in both sexes. Methods: Data were obtained from the Polish National Cancer Registry. The presented metrics included age-standardized 5- and 10-year net survival (NS), median survival times, years of life lost (YLLs), and standardized mortality ratios (SMRs). Results: Between 2000 and 2019, 315,278 patients (2353 men and 312,925 women; male-to-female ratio 1/100) were diagnosed with breast cancer in Poland. In this period, 721,987 YLLs were linked to breast cancer. Women presented a higher 5- and 10-year age-standardized NS than men (5-year NS: 77.33% for women and 65.47% for men, P < 0.001, common language effect size (CL) 1.00; 10-year NS: 68.75% for women and 49.50% for men, P < 0.001, CL 1.00). Between the earliest and latest studied period, namely 2000–2004 and 2015–2019, there was a statistically significant increase only in female survival (+ 7.32 pp, P < 0.001, CL 1.00). SMRs were significantly higher for women than for men (3.35 vs. 2.89, respectively). Conclusion: Over the last two decades, breast cancer survival in Poland has improved significantly. Nonetheless, special attention should be given to the disparities between sexes and the gap in overall improvement of survival rates compared with other European countries.
- 12 December 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (3) , 623-631
Open AccessChanges in the survival of patients with breast cancer: Poland, 2000–2019
Purpose: The main aim of this study was to estimate breast cancer survival in Poland over the period from 2000 to 2019 in both sexes. Methods: Data were obtained from the Polish National Cancer Registry. The presented metrics included age-standardized 5- and 10-year net survival (NS), median survival times, years of life lost (YLLs), and standardized mortality ratios (SMRs). Results: Between 2000 and 2019, 315,278 patients (2353 men and 312,925 women; male-to-female ratio 1/100) were diagnosed with breast cancer in Poland. In this period, 721,987 YLLs were linked to breast cancer. Women presented a higher 5- and 10-year age-standardized NS than men (5-year NS: 77.33% for women and 65.47% for men, P < 0.001, common language effect size (CL) 1.00; 10-year NS: 68.75% for women and 49.50% for men, P < 0.001, CL 1.00). Between the earliest and latest studied period, namely 2000–2004 and 2015–2019, there was a statistically significant increase only in female survival (+ 7.32 pp, P < 0.001, CL 1.00). SMRs were significantly higher for women than for men (3.35 vs. 2.89, respectively). Conclusion: Over the last two decades, breast cancer survival in Poland has improved significantly. Nonetheless, special attention should be given to the disparities between sexes and the gap in overall improvement of survival rates compared with other European countries.
- 15 March 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (5) , 1059-1065
Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999–2020
The aim of this study was to estimate the survival of Polish Burkitt lymphoma/leukemia (BL) patients diagnosed between 1999 and 2017, considering multiple covariates and periods, to reflect changes in BL treatment. We identified all BL patients registered in the Polish National Cancer Registry in 1999–2017. Observed survival (OS) was evaluated deploying the life table method. Univariate and multivariate Cox proportional hazards regression models were fit to generate hazard ratios (HR) and the corresponding 95% confidence intervals (95% CI), describing the association between exposures (sex, age at the diagnosis, year of diagnosis, and region of residence) and time-to-event (death). Two-sided log-rank test was applied to assess the significance of exposures. Overall, 937 BL cases were included in the study (654 men and 283 women). Between the periods 1999–2005 and 2015–2017, the 3-year OS changed from 56.0% (95% CI 50.4 to 62.2%) to 73.8% (68.1 to 80.0%; P < 0.001), and the 5-year OS increased from 53.8% (48.2 to 60.0%) to 73.0% (67.1 to 79.3%; P < 0.001). The death HR was significantly higher in adolescents and young adults’ (AYA) and adults’ groups than in pediatric patients (HR = 3.00, 95% CI 2.05 to 4.39, P < 0.001, for AYA; and HR = 7.30, 5.14 to 10.3, P < 0.001, for adults). During the last two decades, the survival of Polish BL patients has been systematically improving. The death hazard ratio is most significantly associated with the patients’ age at diagnosis and year of diagnosis, and not associated with sex or region of residence.
- 15 March 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (5) , 1059-1065
Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999–2020
The aim of this study was to estimate the survival of Polish Burkitt lymphoma/leukemia (BL) patients diagnosed between 1999 and 2017, considering multiple covariates and periods, to reflect changes in BL treatment. We identified all BL patients registered in the Polish National Cancer Registry in 1999–2017. Observed survival (OS) was evaluated deploying the life table method. Univariate and multivariate Cox proportional hazards regression models were fit to generate hazard ratios (HR) and the corresponding 95% confidence intervals (95% CI), describing the association between exposures (sex, age at the diagnosis, year of diagnosis, and region of residence) and time-to-event (death). Two-sided log-rank test was applied to assess the significance of exposures. Overall, 937 BL cases were included in the study (654 men and 283 women). Between the periods 1999–2005 and 2015–2017, the 3-year OS changed from 56.0% (95% CI 50.4 to 62.2%) to 73.8% (68.1 to 80.0%; P < 0.001), and the 5-year OS increased from 53.8% (48.2 to 60.0%) to 73.0% (67.1 to 79.3%; P < 0.001). The death HR was significantly higher in adolescents and young adults’ (AYA) and adults’ groups than in pediatric patients (HR = 3.00, 95% CI 2.05 to 4.39, P < 0.001, for AYA; and HR = 7.30, 5.14 to 10.3, P < 0.001, for adults). During the last two decades, the survival of Polish BL patients has been systematically improving. The death hazard ratio is most significantly associated with the patients’ age at diagnosis and year of diagnosis, and not associated with sex or region of residence.